Facioscapulohumeral Muscular Dystrophy clinical trials at UCLA

4 in progress, 1 open to eligible people

Showing trials for

  • Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

    open to all eligible people

    The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and reachable workspace, as well as optional muscle biopsy and wearable device (US participants only).

    Los Angeles 5368361, California 5332921 and other locations

  • AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

    Sorry, accepting new patients by invitation only

    A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

    Los Angeles 5368361, California 5332921 and other locations

  • First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy

    Sorry, not currently recruiting here

    The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are: How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working? Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321.

    Los Angeles 5368361, California 5332921 and other locations

  • AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

    Sorry, in progress, not accepting new patients

    A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

    Los Angeles 5368361, California 5332921 and other locations

Our lead scientists for Facioscapulohumeral Muscular Dystrophy research studies include .

Last updated: